ClinicalTrials.gg
RecruitingNCT07347691SMART-ESUSUpdated Jan 16, 2026

AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM

An observational study in Embolic Stroke of Undetermined Source, sponsored by Inha University Hospital. Recruiting at 5 sites in South Korea. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Inha University Hospital · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
92
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Ischemic Stroke with a site in Korea, Republic of — 16 open to participants now, 20 under way, 7 of them phase 3. Ischemic Stroke · Korea, Republic of.

Planned enrollment
25th of 27
92 · median 474
Started
2025
with 3 others
Observational
27 of 88
4 open now
Primary completion
2027-05
later than 8 of 19 live
Registered
83rd of 88
by date

Among the 88 studies in Ischemic Stroke with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 27 observational ones that give a count, is one of 4 that started in 2025, is one of 27 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 83rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

16 of the 88 studies in Ischemic Stroke with a site in Korea, Republic of are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Ischemic Stroke with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.

Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.

Read the detailed description

Embolic Stroke of Undetermined Source (ESUS) accounts for a significant proportion of ischemic strokes, and occult Atrial Fibrillation (AF) is considered a major etiology. While Implantable Cardiac Monitors (ICMs) are the gold standard for long-term rhythm monitoring, identifying patients at the highest risk for AF remains a clinical challenge.

This multicenter, prospective study aims to validate the clinical utility of an artificial intelligence-based electrocardiogram analysis algorithm, "SmartECG-AF," in this specific population. The algorithm analyzes 12-lead ECGs recorded during sinus rhythm to detect subtle signs of electrical remodeling associated with paroxysmal AF.

Enrolled patients with ESUS who have undergone ICM implantation will have their baseline ECGs analyzed by the SmartECG-AF algorithm. Based on the AI-generated probability score, patients will be stratified into a "High Risk" group and a "Low to Intermediate Risk" group. The study will longitudinally track these patients to compare the time-to-event for ICM-detected AF between the two groups. Additionally, the study will evaluate the correlation between the AI risk score and the incidence of Major Adverse Cardiovascular Events (MACE), providing evidence for AI-guided risk stratification in cryptogenic stroke management.

03

Conditions studied

  • Embolic Stroke of Undetermined Source

Browse trials for

Keywords

  • Implantable Cardiac Monitor
  • Artificial Intelligence
  • Deep Learning
  • Electrocardiography
  • Risk Prediction
  • Cryptogenic Stroke
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with Embolic Stroke of Undetermined Source (ESUS) aged 30 years or older who have received or are scheduled to receive an Implantable Cardiac Monitor (ICM). Participants are recruited from five tertiary referral hospitals in South Korea (Inha University Hospital, Jeju National University Hospital, Korea University Guro Hospital, Korea University Ansan Hospital, and Ajou University Hospital).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 30 years or older.
  • Patients diagnosed with Embolic Stroke of Undetermined Source (ESUS) who have undergone or are scheduled for Implantable Cardiac Monitor (ICM) implantation.
  • Patients who have undergone at least one 12-lead examination within 2 weeks before or after the date of ICM implantation.
  • Patients maintaining Sinus Rhythm on ECG at the time of enrollment.
  • Patients who have voluntarily signed the form.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with Atrial Fibrillation (AF) at least once prior to the date of enrollment.
  • Patients whose ICM battery status is at Elective Replacement Interval (ERI), making recording impossible.
  • Patients whose ECGs cannot be analyzed by the AI algorithm (SmartECG-AF) due to severe artifacts or noise, or are incompatible with digital analysis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
92 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • High Risk Group

    Patients classified as having a high risk of atrial fibrillation by the SmartECG-AF AI algorithm.

  • Low to Intermediate Risk Group

    Patients classified as having a low to intermediate risk of atrial fibrillation by the SmartECG-AF AI algorithm.

06

What researchers measure

Primary outcomes

  1. Incidence of Atrial Fibrillation (Time-to-Event)

    Comparison of the cumulative incidence rate of atrial fibrillation (AF) events between the High Risk group and the Low to Intermediate Risk group (classified by SmartECG-AF). AF occurrence is confirmed by reviewing data recorded on the Implantable Cardiac Monitor (ICM).

    Time frame: Up to 12 months

Secondary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE)

    Evaluation of the composite rate of major clinical events including recurrent stroke, hospitalization for heart failure, myocardial infarction, and all-cause death (cardiovascular and non-cardiovascular). The study will analyze the correlation between the occurrence of these events and the AI-predicted risk levels.

    Time frame: Up to 12 months

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality. The informed consent form signed by participants does not include authorization for the release of individual raw data to third parties.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 18 months is below that.

Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Nov 19, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2028
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347691
Lead sponsor
Inha University Hospital
Collaborators
DeepCardio Co., Ltd.
Responsible party
Yong-Soo Baek (Professor, Inha University Hospital) — Principal investigator
First posted
Jan 16, 2026
Start date
Nov 19, 2025
Primary completion
May 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jan 16, 2026

Study contacts

Yong-Soo Baek, MD, PhD
Contact
existsoo@inha.ac.kr
+82-32-890-2200
Hyoung Seok Lee, MD
Contact
hyoungseok_lee@inha.ac.kr
+82-32-890-3575
Yong-Soo Baek, MD, PhD
principal investigator · Inha University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion